Environmental and Lifestyle Hematology: How Air Pollution and Chronic Stress Influence Hematopoiesis, Inflammation, and Vascular Risk

Introduction

Key Definitions

Term	Definition	Clinical relevance
PM2.5	Fine particulate matter with an aerodynamic diameter of 2.5 micrometers or less.	Can reach distal airways and is associated with systemic inflammatory, endothelial, respiratory, and cardiovascular effects.
PM10	Inhalable particulate matter with an aerodynamic diameter of 10 micrometers or less.	Relevant to respiratory exposure but generally penetrates less deeply than PM2.5.
AQI	Air Quality Index, a public-facing scale that communicates short-term air-pollution risk.	Useful for counseling about outdoor activity and exposure reduction during smoke or high-pollution events.
Wildfire smoke	A complex mixture of gases and particles, often containing substantial PM2.5.	Particularly relevant to patients with cardiopulmonary disease, diabetes, CKD, pregnancy, older age, or other limitations in physiologic reserve.
Clonal hematopoiesis	Expansion of blood cells derived from a genetically distinct hematopoietic stem or progenitor cell clone.	May be age-related, therapy-related, or associated with hematologic and cardiovascular risk, depending on the mutation and clinical context.
CHIP	Clonal hematopoiesis of indeterminate potential, generally referring to a detectable myeloid-neoplasm-associated somatic mutation without a diagnosed hematologic malignancy or otherwise unexplained cytopenia.	Associated with increased relative risks of hematologic malignancy and cardiovascular disease, but not an indication for population or exposure-based screening.
HSC	Hematopoietic stem cell.	Long-lived marrow cell capable of self-renewal and multilineage blood-cell production.
HSPC	Hematopoietic stem and progenitor cell.	Includes stem cells and downstream progenitors involved in blood-cell generation.
Emergency myelopoiesis	Accelerated production of myeloid cells during infection, inflammation, tissue injury, or physiologic stress.	Adaptive when acute but potentially maladaptive when sustained or recurrent.
Myeloid bias	Preferential hematopoietic output toward myeloid and megakaryocyte-lineage cells.	Relevant to inflammatory leukocyte production, thrombosis, atherosclerosis, and aging biology.
Endothelial dysfunction	Impaired regulation of vasodilation, inflammation, thrombosis, and vascular barrier function.	A potential mechanistic bridge between pollution exposure and vascular events.
Oxidative stress	An imbalance between reactive oxygen species and antioxidant defenses.	One proposed pathway linking particulate exposure with pulmonary inflammation and vascular injury.
Platelet activation	Increased platelet reactivity or prothrombotic signaling.	Relevant to thrombosis biology but not sufficiently specific for exposure-related clinical testing.
hs-CRP	High-sensitivity C-reactive protein.	A nonspecific marker of systemic inflammation and cardiovascular risk.
NLR	Neutrophil-to-lymphocyte ratio.	A research and risk marker that is not validated as a stand-alone test for pollution- or stress-related injury.
HEPA filtration	High-efficiency particulate air filtration.	A practical method for reducing indoor particulate exposure during smoke events.
MERV 13	An HVAC filter-efficiency rating.	Current public-health guidance favors MERV 13 or higher when compatible with the HVAC system.
NIOSH-approved respirator	A respirator certified by the National Institute for Occupational Safety and Health, such as an N95 or P100.	Can reduce particle inhalation when properly selected, fitted, and worn.

Hematopoiesis is not simply a background maintenance system. It is a dynamic, stress-responsive process that changes in response to infection, inflammation, hypoxia, tissue injury, malignancy, cardiometabolic disease, cigarette smoking, cytotoxic therapy, radiation, and neuroendocrine signaling. In this context, the marrow functions both as a producer of blood cells and as a participant in systemic immune and inflammatory physiology.

Environmental and lifestyle hematology examines whether external exposures, particularly fine particulate air pollution and chronic psychosocial stress, alter blood-cell production in ways that affect inflammatory burden, vascular disease, thrombosis, or hematologic risk.

The answer is cautiously affirmative, but the evidence is uneven. Air pollution is consistently associated with cardiovascular and respiratory disease, systemic inflammation, endothelial dysfunction, autonomic imbalance, platelet activation, and adverse cardiometabolic outcomes. Chronic psychosocial stress is also associated with cardiovascular risk and with behavioral, autonomic, metabolic, endocrine, and inflammatory changes. However, the two exposures do not have identical evidence bases or outcome profiles.

Mechanistic studies support effects on marrow activity and inflammatory leukocyte production. Experimental models show that particulate exposure or chronic variable stress can influence cytokine signaling, sympathetic pathways, marrow niches, and HSPC activity. Human imaging studies provide associative evidence linking stress-related neural activity with marrow metabolic activity, arterial inflammation, and cardiovascular events.

These mechanistic findings do not establish that air pollution or psychosocial stress causes durable HSC reprogramming, CHIP, or clinically actionable marrow disease in humans. Environmental exposure should not become a nonspecific explanation for persistent leukocytosis, thrombocytosis, anemia, cytopenias, abnormal differentials, erythrocytosis, or thrombosis. Such findings still require standard clinical evaluation.

The practical objective is more disciplined: recognize air pollution and chronic stress as possible risk modifiers, especially in patients with established cardiovascular, pulmonary, renal, metabolic, oncologic, or hematologic vulnerability.

Why This Topic Matters Now

Several developments have increased the clinical relevance of environmental and lifestyle hematology.

First, PM2.5 remains a major global public-health concern. The 2021 World Health Organization air-quality guidelines recommend an annual PM2.5 guideline value of 5 µg/m³ and a 24-hour guideline value of 15 µg/m³. These are health-based guideline values rather than enforceable U.S. regulatory standards.

In 2024, the U.S. Environmental Protection Agency strengthened the primary annual PM2.5 National Ambient Air Quality Standard from 12.0 to 9.0 µg/m³. The primary and secondary 24-hour PM2.5 standards were not changed. The distinction between WHO guidance and EPA regulatory standards should remain clear in clinical and public-facing discussions.

Second, wildfire smoke has become a recurrent clinical concern in many regions. Smoke events can abruptly increase PM2.5 across large geographic areas, including communities far from the active fire. Children, older adults, pregnant individuals, and patients with asthma, COPD, heart disease, diabetes, or CKD may be particularly vulnerable. Other patients with limited cardiopulmonary or physiologic reserve may also merit individualized planning.

Third, hematology and vascular medicine are increasingly interconnected. Leukocytes, monocytes, macrophages, platelets, neutrophil extracellular traps, inflammatory cytokines, and clonal hematopoiesis are implicated in atherosclerosis, thrombosis, heart failure biology, and age-associated inflammatory disease.

Fourth, chronic stress is no longer viewed exclusively as a behavioral factor. It can affect sleep, blood pressure, glycemic control, medication adherence, physical activity, substance use, mood, autonomic tone, and inflammatory signaling. Mechanistic and imaging studies suggest a possible brain–bone marrow–artery pathway, although this pathway is not a routine clinical testing framework.

Taken together, these observations support a broader clinical concept: the marrow is integrated into cardiopulmonary, immune, neuroendocrine, metabolic, and vascular physiology.

Hematopoiesis as a Stress-Responsive System

Under basal conditions, HSPCs maintain balanced production of erythrocytes, leukocytes, and platelets. During infection, injury, or other acute physiologic stress, marrow output may shift toward emergency myelopoiesis or thrombopoiesis. Increased production of neutrophils and monocytes can support host defense and tissue repair.

Problems may arise when inflammatory or neuroendocrine signaling is chronic, recurrent, or maladaptive. Cytokines, oxidative stress, sympathetic signaling, glucocorticoid perturbation, hypoxia-inducible pathways, metabolic stress, and marrow-niche remodeling can influence stem-cell cycling and lineage output. In cardiovascular disease, increased inflammatory leukocyte production may contribute to arterial-wall inflammation and plaque progression.

These mechanisms should be interpreted as clinical context, not as diagnoses. A mild neutrophilia after acute illness, corticosteroid therapy, smoke exposure, sleep disruption, or severe stress does not establish a new hematologic syndrome.

Persistent leukocytosis, monocytosis, thrombocytosis, cytopenias, abnormal differentials, circulating immature cells, constitutional symptoms, splenomegaly, unexplained thrombosis, or progressive laboratory abnormalities should be evaluated through conventional hematologic pathways. Environmental or psychosocial history should not delay evaluation for infection, inflammatory disease, iron or nutritional deficiency, medication effects, autoimmune disease, myeloid neoplasia, marrow failure, inherited disorders, or malignancy.

The emerging science should sharpen clinical attention. It should not replace standard diagnostic reasoning.

Air Pollution and the Blood: What Is Established

The strongest evidence concerning air pollution remains cardiovascular and respiratory. PM2.5 exposure is associated with ischemic heart disease, stroke, heart failure, arrhythmias, asthma and COPD exacerbations, lung cancer, and premature mortality.

Supported and proposed mechanisms include pulmonary oxidative stress, autonomic imbalance, systemic inflammatory signaling, endothelial dysfunction, altered vascular tone, changes in plaque biology, and prothrombotic signaling. The relative contribution of each mechanism varies by exposure source, concentration, duration, particle composition, underlying disease, and clinical outcome.

Inflammatory leukocyte biology

PM2.5 exposure has been associated with systemic inflammatory signaling and changes in circulating leukocyte measures. Experimental models also support increased inflammatory leukocyte production and mobilization.

These findings establish biologic plausibility but are not sufficiently specific for diagnostic use. A leukocyte count cannot determine whether an individual patient has experienced clinically important pollution-related marrow activation.

Coagulation and platelet activation

A systematic review and meta-analysis found associations between short-term PM2.5 exposure and selected hemostatic or endothelial biomarkers, including plasminogen activator inhibitor-1, von Willebrand factor, and soluble P-selectin.

These findings are consistent with a potentially more prothrombotic biologic environment. They do not establish that pollution alone caused a thrombotic event in an individual patient, nor do they support routine ordering of coagulation biomarkers after environmental exposure.

Endothelial and vascular inflammation

Air pollution is associated with endothelial dysfunction and vascular inflammation. These effects may be particularly consequential in patients with established coronary disease, stroke, peripheral artery disease, diabetes, CKD, heart failure, advanced age, or other conditions associated with elevated baseline vascular risk.

Environmental risk assessment should complement conventional cardiovascular prevention. It should not be used to justify unproven anti-inflammatory, antiplatelet, anticoagulant, or lipid-lowering treatment outside usual clinical indications.

CBC changes

Studies have reported associations between pollution exposure and white-cell, platelet, or red-cell parameters. Findings are heterogeneous, often modest, and nonspecific.

The CBC is not validated as a screening test for pollution injury. Abnormal results should be interpreted according to their magnitude, duration, trajectory, differential count, accompanying symptoms, medication exposure, and broader clinical context.

Air Pollution and Clonal Hematopoiesis

CHIP involves expansion of blood-cell clones carrying somatic mutations, frequently involving genes such as DNMT3A, TET2, ASXL1, JAK2, and others. CHIP is strongly age-associated and is linked with increased relative risks of hematologic malignancy and atherosclerotic cardiovascular disease. Associations with heart failure, thrombosis, and inflammatory phenotypes have also been reported, although risk varies by gene, clone size, number of mutations, and host factors.

It is biologically plausible that exposures generating oxidative stress or chronic inflammation could influence the selection or expansion of some hematopoietic clones. Plausibility, however, is not proof that air pollution initiates CHIP.

A 2023 analysis of ambient PM2.5 and nitrogen dioxide exposure in two observational cohorts did not identify a statistically supported association with CHIP prevalence. As with any null observational analysis, the study does not exclude small effects, source-specific effects, susceptible subgroups, exposure misclassification, or relationships with clone expansion rather than prevalence.

Overall, direct human evidence linking ambient air pollution with CHIP initiation or clinically meaningful clone expansion remains limited. Experimental findings concerning inflammation and clonal selection should not be extrapolated into population screening recommendations.

There is no evidence-based indication to order CHIP testing solely because a patient lives in a polluted area, has experienced wildfire smoke, or reports chronic psychological stress. Testing should be driven by established hematologic indications, such as persistent unexplained cytopenias or other abnormalities, or performed within appropriate specialist or research programs.

Chronic Stress and Hematopoiesis

Chronic psychosocial stress may influence hematopoiesis through neuroendocrine, autonomic, behavioral, and immune pathways. Sympathetic nervous system activation, altered glucocorticoid signaling, sleep disruption, depression, anxiety, trauma exposure, social adversity, and caregiving burden may converge on inflammatory signaling and leukocyte production.

Experimental evidence supports this concept. In animal models, chronic variable stress can activate HSPCs and increase inflammatory leukocyte output. These experiments establish a potential mechanism but do not prove that ordinary psychosocial stress produces persistent HSC reprogramming in humans.

Human imaging studies have found associations among higher resting amygdalar activity, increased marrow metabolic activity, arterial inflammation, and subsequent cardiovascular events. These findings support a plausible brain–bone marrow–artery pathway. They remain associative and do not establish that neural activity directly caused marrow activation or cardiovascular events.

Amygdalar positron-emission tomography activity and marrow metabolic activity are not routine tools for assessing stress-related cardiovascular risk. Stress should not be used to dismiss persistent hematologic abnormalities. Sustained monocytosis, thrombocytosis, neutrophilia, anemia, cytopenia, or other progressive findings still require standard evaluation.

Stress is best treated as a risk modifier. It can adversely affect blood pressure, glycemic control, adherence, sleep, diet quality, smoking relapse, alcohol use, physical activity, depression, anxiety, and inflammatory burden. These pathways can be clinically important even when they do not produce a specific hematologic diagnosis.

Clinical Implications by Specialty

Cardiology and vascular medicine

Air pollution and chronic stress may be considered nontraditional cardiovascular risk amplifiers. In patients with coronary disease, stroke, peripheral artery disease, heart failure, diabetes, CKD, or known CHIP, clinicians may incorporate environmental and psychosocial exposure counseling into comprehensive risk reduction.

The appropriate response is not indiscriminate inflammatory testing. Priorities remain evidence-based prevention and treatment, including lipid management, blood-pressure control, diabetes management, smoking cessation, physical activity, weight management when appropriate, guideline-directed heart-failure therapy, antithrombotic therapy when otherwise indicated, and attention to depression, anxiety, sleep, and social stressors.

Neither pollution exposure nor CHIP alone should be assumed to create a new indication for aspirin, anticoagulation, anti-inflammatory therapy, or other pharmacologic treatment.

Pulmonology

Pulmonologists may encounter the most immediate effects of particulate exposure. Wildfire smoke and high-PM2.5 events can worsen asthma or COPD symptoms and may be difficult to tolerate in patients with interstitial lung disease or limited respiratory reserve.

Counseling may include access to prescribed medication, adherence to an established action plan, AQI monitoring, indoor air filtration, avoidance of indoor combustion, and use of a properly fitted respirator when outdoor exposure cannot be avoided. New or worsening dyspnea, chest symptoms, hypoxemia, or reduced exercise tolerance should be assessed clinically rather than attributed automatically to smoke exposure.

Nephrology and endocrinology

CKD and diabetes are associated with endothelial dysfunction, inflammation, and elevated vascular risk. CKD is also a common cause of anemia, while diabetes may complicate anemia risk through renal disease, inflammation, medication exposure, nutritional factors, and comorbidity.

Environmental counseling can be integrated into cardiometabolic visits, particularly for patients with recurrent smoke exposure or high baseline cardiovascular risk. This counseling should complement, not replace, established disease management.

Rheumatology

Systemic inflammatory diseases already carry elevated cardiovascular risk. Air pollution or chronic stress may complicate symptom burden, fatigue, disease management, and vascular risk, although direct disease-specific evidence varies.

Clinicians should avoid attributing objective inflammatory changes solely to environmental exposure without considering disease flare, infection, medication effects, thrombosis, malignancy, or another inflammatory condition.

Hematology and oncology

The immediate clinical role for hematologists is selective. Pollution and stress may contribute to inflammatory physiology, but they do not replace standard evaluation of cytopenias, cytoses, thrombosis, marrow failure, or suspected myeloid neoplasia.

In cancer survivors, prior chemotherapy, radiation, aging, tobacco exposure, cardiometabolic disease, and CHIP may interact with cardiovascular risk. Cardio-oncology and hematology collaboration can be useful when interpreting these overlapping risks.

Environmental exposure history alone should not trigger broad genomic sequencing or serial clone monitoring.

Diagnostic Considerations

A targeted exposure history is often more useful than broad laboratory testing. Clinicians may ask whether a patient lives or works near heavy traffic, industrial emissions, wildfire smoke, diesel exhaust, indoor combustion, poor ventilation, or occupational dusts and solvents.

It can also be helpful to ask whether cardiopulmonary symptoms worsen during high-AQI periods and whether the patient has the practical ability, housing conditions, occupational flexibility, and financial resources needed to reduce exposure.

Psychosocial assessment should be similarly practical. Relevant factors may include caregiving burden, shift work, trauma exposure, sleep disruption, depression, anxiety, housing instability, occupational stress, food insecurity, substance use, and social isolation when these factors may affect risk, adherence, or disease control.

Laboratory testing should remain clinically directed. CBC, hs-CRP, fibrinogen, D-dimer, NLR, cytokine panels, platelet-activation markers, and coagulation biomarkers should not be ordered as routine pollution or stress assays. These tests are nonspecific and may generate incidental findings or unnecessary workups.

Persistent, progressive, severe, or clinically discordant abnormalities should be evaluated through established diagnostic pathways.

Table 1. Evidence Gradient for Environmental and Lifestyle Hematology

Domain	Evidence strength	Practical interpretation
PM2.5 and cardiovascular disease	Strong	Consider air pollution an important cardiovascular risk amplifier at the population level.
PM2.5 and respiratory exacerbations	Strong	Counsel susceptible patients before and during smoke or high-AQI events.
PM2.5 and selected coagulation or endothelial biomarkers	Moderate	Supports prothrombotic plausibility but is not diagnostic of individual thrombosis.
PM2.5 and CBC changes	Low to moderate	Reported changes are heterogeneous and nonspecific. Evaluate persistent abnormalities conventionally.
Air pollution and CHIP initiation or prevalence	Limited and inconclusive	Do not screen for CHIP solely because of pollution exposure.
Chronic stress and marrow activation	Moderate mechanistic evidence	Supported primarily by experimental and imaging evidence. Treat stress as a risk modifier, not a hematologic diagnosis.
Stress reduction and hematologic outcomes	Limited	Benefits are best framed through mental health, behavioral, sleep, adherence, and cardiometabolic pathways.
Exposure reduction and hard hematologic outcomes	Insufficient	Exposure reduction is reasonable for general cardiopulmonary risk, but direct hematologic outcome data are limited.

Table 2. Patient Groups Who May Merit More Explicit Counseling

Patient group	Why concern may be greater	Practical clinician action
ASCVD, prior stroke, PAD, or heart failure	Higher baseline vascular vulnerability	Reinforce AQI planning and established cardiovascular prevention.
Asthma or COPD	Direct respiratory susceptibility	Confirm medication access, action plans, and smoke-avoidance strategies.
Interstitial lung disease or limited respiratory reserve	Reduced ability to tolerate additional pulmonary stress	Discuss anticipatory planning and thresholds for reassessment.
CKD or diabetes	Elevated endothelial and cardiovascular risk	Include exposure counseling in comprehensive risk-reduction visits.
Older adults	Greater comorbidity burden and potentially reduced physiologic reserve	Review clean-air planning, medication access, and symptom monitoring.
Pregnancy	Maternal and fetal vulnerability to air pollution	Encourage AQI monitoring and practical exposure reduction.
Children	Greater smoke susceptibility and respirator-fit limitations	Emphasize indoor air quality and age-appropriate public-health guidance.
Outdoor workers	Recurrent exposure and limited ability to avoid outdoor air	Discuss administrative controls, respiratory protection, and occupational-health resources.
Known CHIP	Elevated baseline clonal and cardiovascular risk	Optimize conventional risk factors; do not alter therapy solely because of exposure history.

Table 3. Practical Approach During High-PM2.5 or Wildfire-Smoke Events

Step	Recommendation	Clinical caveat
Assess susceptibility	Identify cardiopulmonary disease, CKD, diabetes, pregnancy, older age, childhood, occupational exposure, or limited physiologic reserve.	Risk depends on exposure intensity, duration, particle composition, and comorbidity.
Monitor conditions	Use the local AQI and follow public-health and emergency-management instructions.	AQI is a population communication tool, not an individual diagnostic test.
Reduce exposure	Limit time in smoky outdoor air and reduce strenuous outdoor exertion when air quality is poor.	Recommendations should reflect AQI severity, symptoms, and baseline disease.
Create cleaner indoor air	Close windows and doors when appropriate, minimize indoor combustion, and use a clean room or portable air cleaner.	Cooling, evacuation safety, housing conditions, and cost may limit feasibility.
Improve HVAC filtration	Use MERV 13 or higher filtration when compatible and use recirculation settings when appropriate.	Incompatible filters may restrict airflow or impair system performance.
Use respiratory protection	When outdoor exposure is unavoidable, use a properly fitted NIOSH-approved respirator such as an N95 or P100.	Fit and correct use are essential. Facial hair, poor fit, discomfort, and patient-specific limitations can reduce effectiveness or tolerability.
Reinforce disease plans	Confirm access to inhalers, medications, monitoring tools, and established action plans.	Environmental counseling is not a substitute for disease treatment.
Reassess concerning symptoms	Evaluate new or worsening chest pain, dyspnea, hypoxemia, neurologic symptoms, syncope, or persistent laboratory abnormalities.	Do not attribute serious or persistent findings solely to pollution or stress.

Therapeutic and Preventive Considerations

Clinical management does not include a pharmacologic treatment directed specifically at presumed pollution- or stress-related marrow activation. The therapeutic framework is exposure reduction, management of established disease, and optimization of conventional risk factors.

During high-PM2.5 or wildfire-smoke periods, reasonable measures include AQI monitoring, reduced outdoor exertion, cleaner indoor-air spaces, portable HEPA filtration, system-compatible higher-efficiency HVAC filtration, reduced indoor combustion, and properly fitted NIOSH-approved respirators when outdoor exposure cannot be avoided.

These interventions are intended to reduce particle exposure. They should not be described as proven treatments for marrow activation, CHIP, or a primary hematologic disorder.

Stress intervention should be framed as medical and behavioral risk management rather than as moral advice. Depending on the clinical indication, approaches may include evaluation and treatment of depression or anxiety, cognitive behavioral therapy, structured physical activity, sleep interventions, mindfulness-based approaches, social support, substance-use treatment, workplace or shift-work accommodations when feasible, and referral to behavioral-health or social services.

Clinicians should not promise that stress management will normalize blood counts, prevent CHIP, reverse marrow reprogramming, or prevent thrombosis. A more defensible message is that psychological health, sleep, adherence, physical activity, and other cardiometabolic behaviors can influence overall health and vascular risk.

Practical Approach for Clinicians

For a patient with coronary disease and repeated smoke exposure, the priority is not CHIP testing. It is evidence-based ASCVD prevention, medication adherence, blood-pressure and lipid management, diabetes control when applicable, symptom planning, and exposure reduction during high-AQI periods.

For a patient with mild, transient leukocytosis after acute illness, corticosteroid treatment, sleep deprivation, smoke exposure, or severe stress, repeat testing after the suspected transient factor has resolved may be reasonable when the overall clinical picture is reassuring. The exposure should not be assumed to be causal without considering other explanations.

Persistent or progressive abnormalities should be evaluated conventionally.

For a patient with known CHIP, pollution and stress counseling may be incorporated into global cardiovascular risk management. Current evidence does not support exposure-based molecular testing, altered sequencing intervals, or intensified clone monitoring in routine practice.

For a patient with asthma, COPD, CKD, diabetes, heart failure, pregnancy, limited physiologic reserve, or unavoidable outdoor occupational exposure, anticipatory counseling before wildfire season or recurrent high-AQI periods may be more useful than reactive advice after symptoms begin.

Limitations of the Evidence

The evidence base has important limitations. Many air-pollution studies are observational and vulnerable to exposure misclassification, residual confounding, socioeconomic gradients, co-pollutants, geographic variability, and differences in particle composition.

PM2.5 from traffic, wildfire smoke, coal combustion, industrial emissions, indoor combustion, and secondary aerosols may not have identical biological effects. Population-level associations also do not establish that a specific exposure caused an individual patient’s event.

Stress research has parallel challenges. Stress is difficult to define and measure and is intertwined with sleep, socioeconomic adversity, trauma, caregiving, diet, physical activity, substance use, mood disorders, and access to care.

Neuroimaging and animal studies provide important biological insight, but they do not automatically translate into routine diagnostic tests or treatment pathways. Human imaging associations are also vulnerable to confounding and do not prove the direction of causality.

For hematopoiesis specifically, much of the strongest mechanistic evidence comes from animal models, imaging studies, or surrogate biomarkers. Human evidence linking pollution or psychosocial stress with durable marrow remodeling, clonal selection, hematologic malignancy, or clinically actionable marrow disease remains insufficient for exposure-based screening.

Future Directions

Future studies should combine personal exposure monitoring, longitudinal blood-count trajectories, inflammatory and hemostatic biomarkers, genomic sequencing, and adjudicated cardiovascular and hematologic outcomes.

Research should distinguish traffic-related, wildfire-related, industrial, occupational, and indoor sources of PM2.5. Studies should also evaluate particle composition, exposure duration, peak versus cumulative exposure, and interactions with smoking, age, socioeconomic conditions, chronic disease, and inherited susceptibility.

CHIP research should focus on whether specific environmental exposures influence mutation acquisition, clone expansion, inflammatory phenotype, vascular events, cancer risk, or treatment response. Longitudinal designs are needed to distinguish CHIP initiation from subsequent clonal selection.

The most clinically useful intervention studies will determine whether exposure reduction changes meaningful clinical outcomes rather than only short-term biomarkers.

Research should also address feasibility and equity. Patients with the greatest cumulative environmental and psychosocial burden may have the least ability to avoid exposure, modify work conditions, improve filtration, relocate temporarily, or access behavioral and medical services.

References

Brook, R. D., Rajagopalan, S., Pope, C. A., Brook, J. R., Bhatnagar, A., Diez-Roux, A. V., Holguin, F., Hong, Y., Luepker, R. V., Mittleman, M. A., Peters, A., Siscovick, D., Smith, S. C., Jr., Whitsel, L., & Kaufman, J. D. (2010). Particulate matter air pollution and cardiovascular disease: An update to the scientific statement from the American Heart Association. Circulation, 121(21), 2331–2378. doi:10.1161/CIR.0b013e3181dbece1. PMID: 20458016.

Centers for Disease Control and Prevention. (2024). Safety guidelines: Wildfires and wildfire smoke. Accessed July 13, 2026.

Heidt, T., Sager, H. B., Courties, G., Dutta, P., Iwamoto, Y., Zaltsman, A., von Zur Muhlen, C., Bode, C., Fricchione, G. L., Denninger, J., Lin, C. P., Vinegoni, C., Libby, P., Swirski, F. K., Weissleder, R., & Nahrendorf, M. (2014). Chronic variable stress activates hematopoietic stem cells. Nature Medicine, 20(7), 754–758. doi:10.1038/nm.3589. PMID: 24952646.

Jaiswal, S., & Libby, P. (2020). Clonal haematopoiesis: Connecting ageing and inflammation in cardiovascular disease. Nature Reviews Cardiology, 17(3), 137–144. doi:10.1038/s41569-019-0247-5. PMID: 31406340.

Jaiswal, S., Natarajan, P., Silver, A. J., Gibson, C. J., Bick, A. G., Shvartz, E., McConkey, M., Gupta, N., Gabriel, S., Ardissino, D., Baber, U., Mehran, R., Fuster, V., Danesh, J., Frossard, P., Saleheen, D., Melander, O., Sukhova, G. K., Neuberg, D., Libby, P., Kathiresan, S., & Ebert, B. L. (2017). Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. New England Journal of Medicine, 377(2), 111–121. doi:10.1056/NEJMoa1701719. PMID: 28636844.

Leiser, C. L., Whitsel, E. A., Reiner, A. P., Rich, S. S., Rotter, J. I., Taylor, K. D., Tracy, R. P., Kooperberg, C., Smith, A. V., Manson, J. E., Mychaleckyj, J. C., Bick, A. G., Szpiro, A. A., & Kaufman, J. D. (2023). Associations between ambient air pollutants and clonal hematopoiesis of indeterminate potential. Cancer Epidemiology, Biomarkers & Prevention, 32(10), 1470–1473. doi:10.1158/1055-9965.EPI-23-0305. PMID: 37466697.

Levine, G. N., Cohen, B. E., Commodore-Mensah, Y., Fleury, J., Huffman, J. C., Khalid, U., Labarthe, D. R., Lavretsky, H., Michos, E. D., Spatz, E. S., & Kubzansky, L. D. (2021). Psychological health, well-being, and the mind-heart-body connection: A scientific statement from the American Heart Association. Circulation, 143(10), e763–e783. doi:10.1161/CIR.0000000000000947. PMID: 33486973.

Poller, W. C., Nahrendorf, M., & Swirski, F. K. (2020). Hematopoiesis and cardiovascular disease. Circulation Research, 126(8), 1061–1085. doi:10.1161/CIRCRESAHA.120.315895. PMID: 32271679.

Rajagopalan, S., Al-Kindi, S. G., & Brook, R. D. (2018). Air pollution and cardiovascular disease: JACC state-of-the-art review. Journal of the American College of Cardiology, 72(17), 2054–2070. doi:10.1016/j.jacc.2018.07.099. PMID: 30336830.

Rajagopalan, S., Brauer, M., Bhatnagar, A., Bhatt, D. L., Brook, J. R., Huang, W., Münzel, T., Newby, D., Siegel, J., & Brook, R. D. (2020). Personal-level protective actions against particulate matter air pollution exposure: A scientific statement from the American Heart Association. Circulation, 142(23), e411–e431. doi:10.1161/CIR.0000000000000931. PMID: 33150789.

Schloss, M. J., Swirski, F. K., & Nahrendorf, M. (2020). Modifiable cardiovascular risk, hematopoiesis, and innate immunity. Circulation Research, 126(9), 1242–1259. doi:10.1161/CIRCRESAHA.120.315936. PMID: 32324501.

Tawakol, A., Ishai, A., Takx, R. A. P., Figueroa, A. L., Ali, A., Kaiser, Y., Truong, Q. A., Solomon, C. J. E., Calcagno, C., Mani, V., Tang, C. Y., Mulder, W. J. M., Murrough, J. W., Hoffmann, U., Nahrendorf, M., Shin, L. M., Fayad, Z. A., & Pitman, R. K. (2017). Relation between resting amygdalar activity and cardiovascular events: A longitudinal and cohort study. The Lancet, 389(10071), 834–845. doi:10.1016/S0140-6736(16)31714-7. PMID: 28088338.

U.S. Environmental Protection Agency. (2024). Final reconsideration of the National Ambient Air Quality Standards for particulate matter. Updated April 14, 2026. Accessed July 13, 2026.

U.S. Environmental Protection Agency. (2025). Create a clean room to protect indoor air quality during a wildfire. Accessed July 13, 2026.

Wang, K., Wang, W., Lei, L., Yang, L., Liu, Q., Ren, L., & Wu, S. (2022). Association between short-term exposure to ambient air pollution and biomarkers of coagulation: A systematic review and meta-analysis. Environmental Research, 215, 114210. doi:10.1016/j.envres.2022.114210. PMID: 36030918.

World Health Organization. (2021). WHO global air quality guidelines: Particulate matter, ozone, nitrogen dioxide, sulfur dioxide and carbon monoxide. World Health Organization.